Providence Expands AI-Powered Genetic Screening to Detect Inherited Cancer Risks Earlier

Providence is expanding the use of artificial intelligence (AI) to identify cancer patients who may carry inherited genetic mutations, aiming to improve early detection and ensure more eligible patients receive genetic testing.

The healthcare system's Precision4ME program, now operating across three Providence hospitals in Orange County, uses AI to analyze pathology reports and flag patients who meet established guidelines for germline genetic testing. Genetic counselors then review those cases before patients are offered further assessment and testing. According to Providence, the system is designed to reduce manual review while increasing access to precision medicine. 

The program recently drew attention after Laguna Niguel resident Merritt Johnson credited it with identifying an inherited Lynch syndrome mutation that ultimately led physicians to detect an early-stage stomach tumor before symptoms appeared, according to reporting by the Orange County Register.

AI Automates Case Identification for Genetic Testing

Precision4ME focuses on patients whose pathology results suggest an inherited predisposition to cancers including colorectal, breast, ovarian, pancreatic, and prostate cancer. Rather than replacing clinicians, the AI system automates the initial review of pathology reports so genetic counselors can concentrate on patient consultations and follow-up care. 

According to Providence genetic counselor Dillon van den Berg, the technology also helps clinicians navigate the growing volume of medical literature more efficiently by surfacing relevant evidence that can support faster clinical decision-making, while keeping patient data inside Providence's private systems.

Providence says patient information processed through Precision4ME is not used to train large language models, addressing one of the primary concerns surrounding AI adoption in healthcare.

The program builds on Providence's broader strategy of embedding AI into clinical workflows. Earlier this year, the health system expanded Epic-native AI capabilities to reduce administrative work and streamline clinician workflows, reflecting a broader effort to integrate AI directly into existing care delivery systems rather than deploying standalone tools. 

Focus Shifts From Diagnosis to Prevention

Providence launched its pathology screening initiative roughly 15 years ago and has progressively incorporated genomics and AI as the technology matured. Precision4ME represents part of a larger genomics portfolio that includes programs for hereditary cancer risk assessment, precision oncology, and population-scale genomic screening. 

According to Sandra Brown, Senior Manager of the program, identifying inherited mutations extends beyond the individual patient because first-degree relatives may carry the same genetic risk. Providence therefore offers eligible family members a limited period of complimentary genetic testing after a mutation is identified.

The health system reported that it has achieved a 95% referral rate for patients eligible for genetic testing, with nearly 80% completing testing. Over the past six years, the program has identified nearly 8,000 Orange County cancer patients who met testing criteria and detected roughly 900 clinically significant inherited mutations, including BRCA and Lynch syndrome variants, according to Providence.

The initiative reflects a broader trend across healthcare toward using AI earlier in the patient journey, particularly in genomics and cancer prevention. Similar efforts include AI-assisted cancer detection technologies and genomic analysis platforms that seek to identify high-risk patients before disease progresses. For example, recent work on AI-powered blood-based cancer detection has expanded the use of AI beyond diagnosis into earlier risk identification and screening.